Abivax Sa · EURONEXT:ABVX
Abivax Sa — Investor Presentation (May 2020)
18 slides from Abivax Sa's investor presentation, May 2020
Slide 1: Establishing ABX464's anti-inflammatory, antiviral and tissue repair properties to prevent and treat COVID-19
Establishing ABX464’s anti- inflammatory, antiviral and tissue repair properties to prevent and treat COVID-19 Abivax, a late-stage clinical biotech company May 2020
Slide 2: Forward looking statements
Forward looking statements This presentation contains information pertaining to Abivax S.A. (“Abivax”). Neither Abivax, nor its management, shareholders, directors, advisors, employees or representatives make any representation or warranty, express or implied, as to the fairness, the accuracy, compl
Slide 3: Key company facts
Key company facts Milestones Shareholder structure1 and market cap2 Founded in 2013 Sept. 2018: Focus ABX464 on chronic inflammation 34% Truffle Capital by Truffle Capital Sofinnova € 250m 46% Board & management Abivax went May 2020: ABX464 to 2% Incubator & founders public in June 2015, treat acute
Slide 4: Abivax: A strong and diversified pipeline
Abivax: A strong and diversified pipeline Lead generation Research Preclinical Phase 1 Phase 2 Phase 3 ABX464 Phase 2b ongoing Ulcerative colitis Inflammatory diseases ABX464 Phase 2b: FPI: H2, 2020 Crohn’s disease ABX464 Phase 2a ongoing Rheumatoid arthritis ABX464 Phase 2b/3 ongoing COVID-19 HIV A
Slide 5: ABX464: Targeting inflammatory diseases and COVID-19 markets
ABX464: Targeting inflammatory diseases and COVID-19 markets Discovered in proprietary Abivax compound library, biased Inflammatory disease to modulate RNA biogenesis; Close collaboration with market size(1) EVOTEC greater than Small molecule (quinoline), administered as an oral capsule $ 90 B (once
Slide 6: COVID-19 infection and pathology
COVID-19 infection and pathology Mild and moderate Recovery disease COVID-19 First Diagnosis infection symptoms (PCR) Acute Severe Respiratory Multi-Organ Distress Death 2 – 10 days disease Failure Syndrome Cytokine Storm ICU admission Syndrome Mostly in elderly and Hyper- other high-risk patients I
Slide 7: ABX464 COVID-19 Development Rationale
ABX464 COVID-19 Development Rationale Antiviral: ABX464 inhibits SARS-CoV-2 (COVID-19 virus) in vitro replication in human respiratory epithelium: Inhibition of COVID-19 viral replication comparable to Remdesivir Anti-inflammatory: ABX464 has demonstrated potent anti- inflammatory properties in seve
Slide 8: Mechanistic rationale for ABX464 to treat COVID-19 infection
Mechanistic rationale for ABX464 to treat COVID-19 infection Three shots on goal * The Lancet, March 16, 2020 Mobilizing the immune system to fight inflammatory and viral diseases, as well as cancer 8 Puja Mehta et al.
Slide 9: ABX464 specifically and rapidly upregulates miR-124
ABX464 specifically and rapidly upregulates miR-124 10-fold within 24 hours in human PBMCs (in vitro results) miR-124 upregulation Vs. time of ABX464 treatment 14 Mean fold-change compared to DMSO 12 ABX464 (5 µM) 10 8 6 4 2 0 2h 4h 8h 12h 24h Mobilizing the immune system to fight inflammatory and v
Slide 10: ABX464 novel mechanism of action: upregulation of miR-124 reduces pro-inflammatory cytokines
ABX464 novel mechanism of action: Potent and specific upregulation of miR-124 leads to reduction of pro-inflammatory cytokines Both systemic and local inflammatory sites Established miR-124 targets: (translation ) Outcome ABX 464 MCP-1/ 1 CBC MCP-1/CCL2 CCL2 IL-6 STAT 3 IL-17 miR-124 TNFa JAK pathwa
Slide 11: ABX464 showed efficacy in the DSS mouse model
ABX464 showed efficacy in the DSS mouse model* ABX464 protects mice from death DSS without ABX464 leads ABX464 protects intestinal in the DSS mouse model to intestinal damage structure Relative weight (%) 120 Induction of inflammation by DSS ABX464. 20 days ABX464. 60 days 110 100 90 Days 80 0 5 10
Slide 12: Tissue repair in an ABX464 treated UC patient
Tissue repair in an ABX464 treated UC patient Courtesy of Prof. Severine Vermeire Before ABX464 After ABX464 Mobilizing the immune system to fight inflammatory and viral diseases, as well as cancer 12
Slide 13: Reduction of COVID-19 replication in vitro: comparable efficacy between Remdesivir and ABX464
Reduction of COVID-19 replication in an in vitro reconstituted human airway epithelial model: Comparable efficacy between Remdesivir and ABX464 Infectious titrations TCID50 at 48 hours post infection Mobilizing the immune system to fight inflammatory and viral diseases, as well as cancer 13
Slide 14: ABX464 showed a good safety profile during clinical development of the 50 mg dosage form
ABX464 showed a good safety profile during clinical development of the 50 mg dosage form Safety profile consistent Overall: Generally well tolerated with no deaths, no malignancies, no severe infections, no significant changes in with previous and ongoing the laboratory parameters including blood ce
Slide 15: European Phase 2/3 clinical trial miR-AGE: High-risk patients, prior to respiratory distress
European Phase 2/3 clinical trial miR-AGE : High-risk patients, PRIOR to respiratory distress ➢ Early treatment of high-risk patients infected with COVID-19 ➢ Phase 2b/3 study, placebo-controlled and randomized ➢ Main objective: A Phase 2b/3, randomized, double blind, placebo-controlled study of ABX
Slide 16: ABX464 Supply available for COVID-19 clinical trials and scalable
ABX464 Supply available for COVID-19 clinical trials and scalable French Manufacturers (Seqens / Delpharm / Creapharm) Supplies available for miR-AGE study Current drug supplies allow the treatment of around 2 500 patients during 4 weeks / 50 mg daily Current drug substance supplies allow treatment
Slide 17: ABX464 COVID-19 Bpifrance funding
ABX464 COVID-19 Bpifrance funding Total amount of € 36m is made of € 20,1m grant (non-refundable) and € 15,9m loan (refundable when ABX464 is reaching commercial stage) Total amount of € 36m is funding miR-AGE study as well as additional costs for ABX464 development and manufacturing scale up, requi
Slide 18: Highly experienced Executive Committee
Highly experienced Executive Committee • Prof. Hartmut Ehrlich, M.D. • Chief Executive Officer Former Head of Global R&D, Baxter BioScience • Didier Blondel • Pierre Courteille • Jérôme Denis • Alexandra Pearce • Chief Financial Officer & Pharmacist, MBA Ph.D. Ph.D. Board Secretary • Chief Commercia